Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre, Open Label, Prospective, Randomised Clinical Trial to Evaluate the Effectiveness of Abacavir 600 mg+ Lamivudine 300 mg as QD+ Efavirenz 600 mg QD Versus Kaletra 400/100 mg BID as Initial Antiretroviral Treatment

NCT00318123 is registered in ClinicalTrials.gov with Germans Trias i Pujol Hospital as lead sponsor.

NCT NCT00318123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00318123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre, Open Label, Prospective, Randomised Clinical Trial to Evaluate the Effectiveness of Abacavir 600 mg+ Lamivudine 300 mg as QD+ Efavirenz 600 mg QD Versus Kaletra 400/100 mg BID as Initial Antiretroviral Treatment
Lead sponsor
Germans Trias i Pujol Hospital
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2004
Completion date
April 30, 2007
Enrollment
126 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections